Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label mass balance study of [14C]-AZ-3102 in healthy male subjects
NL-OMON60963Phase 1Completed
- Sponsor
- Azafaros
- Start
- Jul 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nizubaglustat in Glycosphingolipid lysosomal storage disease (GSL-LSD), sponsored by Azafaros. Primary endpoints: Mass balance, Metabolic profile and 4 more. Started Jul 2023; status: completed.
02
Drugs
nizubaglustat
03
Conditions
Glycosphingolipid lysosomal storage disease (GSL-LSD)
Beyond the preview
Go deeper on NL-OMON60963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60963.